1-9 of 9
Shyamala Navada
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

John O. Mascarenhas, Claire Harrison, Prithviraj Bose, Jean-Jacques Kiladjian, Alessandro Lucchesi, Alessandro Maria Vannucchi, Tymara Berry, Jennifer Riggs, Lixian Peng, Fei Huang, Ying Wan, Vivian Rodolf, Judy Ho, Shyamala Navada, Rami S. Komrokji
Journal: Blood
Blood (2024) 144 (Supplement 1): 1808.1.
https://doi.org/10.1182/blood-2024-199235
Published: 2024
Journal Articles

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Uwe Platzbecker, Valeria Santini, Amer M. Zeidan, Mikkael A. Sekeres, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, Yazan F Madanat, Maria Diez-Campelo, David Valcarcel, Anna Jonasova, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Michael R. Savona, Rami S. Komrokji
Journal: Blood
Blood (2024) 144 (Supplement 1): 352.
https://doi.org/10.1182/blood-2024-203612
Published: 2024
Journal Articles

PEPN2312: A Pediatric Early Phase Clinical Trials Network (PEP-CTN) Phase 1 Trial of Imetelstat with Fludarabine/Cytarabine in Pediatric Patients with Relapsed/Refractory AML, MDS, or JMML

Alexandra McLean Stevens, Maureen M. O'Brien, Xiaowei Liu, Charles G Minard, Olga Militano, Joel M Reid, Shyamala Navada, Todd M Cooper, Sarah K. Tasian, Elizabeth Fox, Brenda J. Weigel
Journal: Blood
Blood (2024) 144 (Supplement 1): 4265.4.
https://doi.org/10.1182/blood-2024-207907
Published: 2024
Journal Articles

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

Mikkael A. Sekeres, Valeria Santini, Amer M. Zeidan, Uwe Platzbecker, Rami S. Komrokji, Maria Diez-Campelo, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, David Valcarcel, Antoine Regnault, Kristin Creel, Nishan Sengupta, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Shyamala Navada, Esther Natalie Oliva
Journal: Blood
Blood (2024) 144 (Supplement 1): 3210.
https://doi.org/10.1182/blood-2024-199636
Published: 2024
Journal Articles

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Rami S. Komrokji, Valeria Santini, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, Tymara Berry, Laurie Sherman, Shyamala Navada, Faye M. Feller, Libo Sun, Qi Xia, Ying Wan, Fei Huang, Amer M. Zeidan, Uwe Platzbecker
Journal: Blood
Blood (2023) 142 (Supplement 1): 194.
https://doi.org/10.1182/blood-2023-181237
Published: 2023
Journal Articles

Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndrome (LR-MDS) Is Associated with Better Survival: A Population Level Analysis Based on a Large US Health Insurance Claims Database

Rami S. Komrokji, Nishan Sengupta, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, Tim Werwath, Zhuoer Xie, Eric Padron, David A Sallman
Journal: Blood
Blood (2023) 142 (Supplement 1): 2440.
https://doi.org/10.1182/blood-2023-180797
Published: 2023
Journal Articles

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Amer M. Zeidan, Michael R. Savona, Yazan F. Madanat, Pierre Fenaux, Rami S. Komrokji, Anna Jonášová, Thomas Illmer, Libo Sun, Tymara Berry, Faye M. Feller, Shyamala Navada, Valeria Santini, Uwe Platzbecker
Journal: Blood
Blood (2023) 142 (Supplement 1): 6478.
https://doi.org/10.1182/blood-2023-180962
Published: 2023
Journal Articles

Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)

Uwe Platzbecker, Rami S. Komrokji, Amer M. Zeidan, Pierre Fenaux, Mikkael A. Sekeres, Michael R. Savona, Yazan F. Madanat, Anna Jonášová, Thomas Illmer, Laurie Sherman, Tymara Berry, Jennifer Riggs, Qi Xia, Shyamala Navada, Ying Wan, Fei Huang, Faye M. Feller, Valeria Santini
Journal: Blood
Blood (2023) 142 (Supplement 1): 4605.
https://doi.org/10.1182/blood-2023-181154
Published: 2023
Journal Articles

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Mikkael A. Sekeres, Maria Diez-Campelo, Amer M. Zeidan, Uwe Platzbecker, Antoine Regnault, Kristin Creel, Nishan Sengupta, Ying Wan, Libo Sun, Qi Xia, Tymara Berry, Souria Dougherty, Sheetal Shah, Shyamala Navada, Valeria Santini, David Valcárcel
Journal: Blood
Blood (2023) 142 (Supplement 1): 6479.
https://doi.org/10.1182/blood-2023-181103
Published: 2023